pravastatin has been researched along with tacrolimus in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Anand, R; Burrows, L; Genyk, Y; Knight, R; Moran, V; Schwartz, B | 1 |
| Fricker, FJ; Harker, K; Kahler, DA; Penson, MG; Schowengerdt, KO; Thompson, JR; Williams, BJ | 1 |
| Antikainen, M; Hedman, M; Holmberg, C; Neuvonen, M; Neuvonen, PJ | 1 |
| Asberg, A; Hermann, M; Holdaas, H; Lemahieu, WP; Maes, BD; Vanrenterghem, Y; Verbeke, K | 1 |
| Heemann, U; Kohnle, M; Kribben, A; Philipp, T; Pietruck, F; Witzke, O | 1 |
| Serón, D | 1 |
| Iwagaki, H; Kanke, T; Liu, K; Nishibori, M; Takahashi, HK; Tanaka, N; Yagi, T; Yoshino, T | 1 |
1 review(s) available for pravastatin and tacrolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for pravastatin and tacrolimus
| Article | Year |
|---|---|
Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients.
Topics: Adult; Aged; Anticholesteremic Agents; Cyclosporine; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gingival Hyperplasia; Hirsutism; Humans; Hyperlipidemias; Immunosuppressive Agents; Indoles; Kidney Transplantation; Lovastatin; Male; Middle Aged; Pravastatin; Tacrolimus | 1998 |
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Topics: Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pravastatin; Pyrroles; Simvastatin; Tacrolimus; Time Factors | 2005 |
Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cyclosporine; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Kidney Transplantation; Liver; Male; Middle Aged; Muscle, Skeletal; Pravastatin; Simvastatin; Tacrolimus | 2006 |
11 other study(ies) available for pravastatin and tacrolimus
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients.
Topics: Adolescent; Adult; Child; Cyclosporine; Drug Therapy, Combination; Female; Graft Rejection; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunosuppression Therapy; Immunosuppressive Agents; Lipids; Male; Pravastatin; Retrospective Studies; Tacrolimus; Transaminases | 2001 |
Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression.
Topics: Administration, Oral; Adolescent; Anticholesteremic Agents; Area Under Curve; Azathioprine; Calcineurin Inhibitors; Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Drug Interactions; Female; Heart Transplantation; Humans; Immunosuppressive Agents; Male; Methylprednisolone; Mycophenolic Acid; Pravastatin; Tacrolimus; Triglycerides | 2004 |
Management of cardiovascular risk in patients receiving calcineurin inhibitors--a case report.
Topics: Acenocoumarol; Amiodarone; Angioplasty; Calcineurin Inhibitors; Carbazoles; Carvedilol; Cyclosporine; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Immunosuppressive Agents; Indoles; Kidney Transplantation; Male; Middle Aged; Myocardial Infarction; Nitroglycerin; Postoperative Complications; Pravastatin; Prednisone; Propanolamines; Risk Factors; Tacrolimus; Treatment Outcome | 2006 |
Action profiles of statins and calcineurin inhibitors during human mixed lymphocyte reaction.
Topics: Calcineurin Inhibitors; CD40 Antigens; Cell Proliferation; Cyclosporine; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Intercellular Adhesion Molecule-1; Interferon-gamma; Interleukin-12; Interleukin-18; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Mevalonic Acid; Monocytes; Naphthalenes; Oxazines; Pravastatin; T-Lymphocytes; Tacrolimus | 2007 |